Beta Preserve
Currently recruiting
A randomised, double-blind, Phase 3 study to investigate efficacy and safety of teplizumab compared with placebo in participants 1 to 25 years of age with recently diagnosed Stage 3 Type 1 Diabetes (T1D).
Recruiting sites:
- Chelsea and Westminster Hospital, London
- King’s College Hospital, Denmark Hill, London
Summary
Trial of a new medication in people with type 1 diabetes aged 1-25 and within 8 weeks of diagnosis.
Aim
To investigate whether this medication can improve blood glucose control or prandial insulin use in people recently diagnosed with type 1 diabetes.
Contact us
A study specific page will be created on SanofiStudies.com, containing a list of all the UK sites and a contact form for each one. The direct link will be provided when available.
Eligibility to take part
- Age 1-25 years
- Diagnosed with type 1 diabetes in the last 8 weeks
If you are interested in taking part, please click the “Get Involved” button below:
What will I be asked to do?
Participants will receive either teplizumab or placebo through IV infusions over two 12-day periods, six months apart. They will attend regular study visits over 18 months for blood tests, physical exams, and questionnaires. Participants will wear a continuous glucose monitor periodically and will keep a diary of insulin use and low/high blood sugar events.. They will continue their usual diabetes care throughout the study.
Who is running this study?
This study is being run by Sanofi UK. It is funded by Sanofi-Aventis Research and Development.
